Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 11.72
(7.33%)
CAD 11.72
(7.33%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 21.16 Million USD | 2.36% |
| 2022 | 20.67 Million USD | -5.78% |
| 2021 | 21.94 Million USD | 1.56% |
| 2020 | 21.6 Million USD | -3.76% |
| 2019 | 22.45 Million USD | -1.31% |
| 2018 | 22.74 Million USD | -43.58% |
| 2017 | 40.32 Million USD | -1.03% |
| 2016 | 40.74 Million USD | 18.4% |
| 2015 | 34.4 Million USD | 316.62% |
| 2014 | 8.25 Million USD | -67.44% |
| 2013 | 25.36 Million USD | 198.38% |
| 2012 | 8.5 Million USD | 143.22% |
| 2011 | 3.49 Million USD | -35.08% |
| 2010 | 5.38 Million USD | 77.34% |
| 2009 | 3.03 Million USD | 139.46% |
| 2008 | 1.26 Million USD | 133.38% |
| 2007 | 543.26 Thousand USD | -30.26% |
| 2006 | 778.99 Thousand USD | 20.47% |
| 2005 | 646.63 Thousand USD | -97.46% |
| 2004 | 25.41 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.86 Million USD | 19.25% |
| 2024 Q2 | 5.3 Million USD | -9.6% |
| 2023 Q2 | 5.28 Million USD | 8.23% |
| 2023 Q4 | 4.92 Million USD | -18.92% |
| 2023 Q1 | 4.88 Million USD | -0.47% |
| 2023 FY | 21.16 Million USD | 2.36% |
| 2023 Q3 | 6.06 Million USD | 14.75% |
| 2022 Q2 | 5.55 Million USD | 2.62% |
| 2022 Q4 | 4.9 Million USD | 2.44% |
| 2022 FY | 20.67 Million USD | -5.78% |
| 2022 Q1 | 5.41 Million USD | -7.45% |
| 2022 Q3 | 4.79 Million USD | -13.78% |
| 2021 Q4 | 5.85 Million USD | 29.64% |
| 2021 Q1 | 5.44 Million USD | -11.4% |
| 2021 Q2 | 6.13 Million USD | 12.52% |
| 2021 Q3 | 4.51 Million USD | -26.36% |
| 2021 FY | 21.94 Million USD | 1.56% |
| 2020 FY | 21.6 Million USD | -3.76% |
| 2020 Q1 | 5.9 Million USD | -0.14% |
| 2020 Q2 | 4.7 Million USD | -20.2% |
| 2020 Q3 | 4.85 Million USD | 3.02% |
| 2020 Q4 | 6.14 Million USD | 26.78% |
| 2019 Q2 | 5.59 Million USD | 8.81% |
| 2019 Q4 | 5.9 Million USD | 1.79% |
| 2019 Q3 | 5.8 Million USD | 3.72% |
| 2019 FY | 22.45 Million USD | -1.31% |
| 2019 Q1 | 5.14 Million USD | -19.54% |
| 2018 Q2 | 6.95 Million USD | 52.13% |
| 2018 FY | 22.74 Million USD | -43.58% |
| 2018 Q4 | 6.39 Million USD | 32.42% |
| 2018 Q3 | 4.82 Million USD | -30.62% |
| 2018 Q1 | 4.57 Million USD | -62.43% |
| 2017 Q3 | 10.09 Million USD | 1.77% |
| 2017 Q1 | 8.14 Million USD | -23.77% |
| 2017 FY | 40.32 Million USD | -1.03% |
| 2017 Q4 | 12.17 Million USD | 20.63% |
| 2017 Q2 | 9.91 Million USD | 21.76% |
| 2016 Q3 | 9.26 Million USD | -20.78% |
| 2016 FY | 40.74 Million USD | 18.4% |
| 2016 Q2 | 11.69 Million USD | 28.61% |
| 2016 Q1 | 9.09 Million USD | -6.37% |
| 2016 Q4 | 10.68 Million USD | 15.28% |
| 2015 Q3 | 8.46 Million USD | -4.24% |
| 2015 FY | 34.4 Million USD | 316.62% |
| 2015 Q4 | 9.71 Million USD | 14.82% |
| 2015 Q2 | 8.83 Million USD | 21.96% |
| 2015 Q1 | 7.24 Million USD | 12.0% |
| 2014 Q4 | 6.46 Million USD | 0.12% |
| 2014 FY | 8.25 Million USD | -67.44% |
| 2014 Q1 | 7.12 Million USD | -37.12% |
| 2014 Q2 | 8.18 Million USD | 14.86% |
| 2014 Q3 | 6.46 Million USD | -21.09% |
| 2013 Q4 | 11.33 Million USD | 107.47% |
| 2013 Q2 | 5.27 Million USD | 62.89% |
| 2013 Q1 | 3.23 Million USD | 13.36% |
| 2013 FY | 25.36 Million USD | 198.38% |
| 2013 Q3 | 5.46 Million USD | 3.63% |
| 2012 Q4 | 2.85 Million USD | 32.67% |
| 2012 FY | 8.5 Million USD | 143.22% |
| 2012 Q1 | 1.81 Million USD | 70.4% |
| 2012 Q2 | 1.6 Million USD | -11.76% |
| 2012 Q3 | 2.15 Million USD | 34.36% |
| 2011 Q2 | 750.62 Thousand USD | 8.08% |
| 2011 FY | 3.49 Million USD | -35.08% |
| 2011 Q1 | 694.5 Thousand USD | -46.46% |
| 2011 Q4 | 1.06 Million USD | -1.31% |
| 2011 Q3 | 1.07 Million USD | 43.79% |
| 2010 FY | 5.38 Million USD | 77.34% |
| 2010 Q3 | 1.04 Million USD | -50.21% |
| 2010 Q2 | 2.1 Million USD | 133.66% |
| 2010 Q1 | 900.52 Thousand USD | 7.17% |
| 2010 Q4 | 1.29 Million USD | 23.81% |
| 2009 Q4 | 840.28 Thousand USD | -15.82% |
| 2009 FY | 3.03 Million USD | 139.46% |
| 2009 Q1 | 476.75 Thousand USD | 133.47% |
| 2009 Q2 | 584 Thousand USD | 22.5% |
| 2009 Q3 | 998.22 Thousand USD | 70.93% |
| 2008 Q4 | 204.2 Thousand USD | -67.83% |
| 2008 FY | 1.26 Million USD | 133.38% |
| 2008 Q3 | 634.8 Thousand USD | 133.25% |
| 2008 Q2 | 272.15 Thousand USD | 58.27% |
| 2008 Q1 | 171.96 Thousand USD | 4.51% |
| 2007 Q4 | 164.54 Thousand USD | 9.64% |
| 2007 Q3 | 150.08 Thousand USD | -29.62% |
| 2007 FY | 543.26 Thousand USD | -30.26% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | 213.24 Thousand USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | 778.99 Thousand USD | 20.47% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | 646.63 Thousand USD | -97.46% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q2 | 4.37 Million USD | 81.12% |
| 2004 Q1 | 2.41 Million USD | 0.0% |
| 2004 Q3 | 6.29 Million USD | 43.81% |
| 2004 FY | 25.41 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aurora Cannabis Inc. | 270.28 Million CAD | 92.17% |
| Avicanna Inc. | 16.79 Million CAD | -26.028% |
| Avant Brands Inc. | 26.34 Million CAD | 19.671% |
| Cardiol Therapeutics Inc. | - CAD | -Infinity% |
| Crescita Therapeutics Inc. | 17.52 Million CAD | -20.774% |
| Knight Therapeutics Inc. | 328.19 Million CAD | 93.552% |
| MediPharm Labs Corp. | 33.06 Million CAD | 35.993% |
| OrganiGram Holdings Inc. | 149.2 Million CAD | 85.817% |
| Canopy Growth Corporation | 297.14 Million CAD | 92.878% |
| Willow Biosciences Inc. | 1.17 Million CAD | -1705.631% |
| Auxly Cannabis Group Inc. | 101.07 Million CAD | 79.064% |